MedTrace Logo

Proof of Concept Study of OC000459 in Eosinophilic Esophagitis

NCT01056783 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2012-01-05

No results posted yet for this study

Summary

This will be a randomised, double blind, placebo controlled, parallel group evaluation of the effect of OC000459 given orally for eight weeks on active eosinophilic esophagitis.

Conditions

  • Eosinophilic Esophagitis

Interventions

DRUG

OC000459

OC000459 100mg, twice daily, tablet

DRUG

Placebo

Placebo tablets to match OC000459 tablets, twice daily

Sponsors & Collaborators

  • Oxagen Ltd

    lead INDUSTRY

Principal Investigators

  • Alex Straumann, Dr · Swiss EoE Research Group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01056783 on ClinicalTrials.gov